Back to search

Article

Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: A Network Meta-Analysis of Randomized Controlled Trials

2025-05-21

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose: </bold>In patients with HR-positive, HER2-negative advanced breast cancer who have progressed after CDK4/6 inhibitors, the optimal selection of subsequent therapies remains uncertain. This study employs a Bayesian network meta-analysis to evaluate the efficacy and safety of different treatment options. <bold>Methods: </bold>We conducted a comprehensive literature search i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
84e5e737-6a33-506e-b349-0d1d0248ff96
DOI
10.21203/rs.3.rs-6659707/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: A Network Meta-Analysis of Randomized Controlled TrialsDOI 10.21203/rs.3.rs-6659707/v1
Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity
Progression free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysisSemantic proximity
Comparing efficacy and safety of Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Bayesian network meta-regression analysesSemantic proximity
Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: A network meta-analysisSemantic proximity
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity
The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity
Real-World Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multi- institutional Retrospective Cohort StudySemantic proximity
TP53 mutation is associated with resistance to CDK4/6 Inhibitors, but not to Immune Checkpoint Inhibitors, in ER-positive/HER2-negative Breast Cancer: Real-World perspectiveSemantic proximity
Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.Semantic proximity
Research on therapeutic clinical trials including immunotherapy in Triple- negative Breast cancer: A bibliometric analysisSemantic proximity
Exploratory Bayesian Synthesis of Targeted Agents Combined With Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer: A Network Meta-analysis of Single-Arm StudiesSemantic proximity
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.